Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Landos Biopharma","sponsor":"LianBio","pharmaFlowCategory":"D","amount":"$218.0 million","upfrontCash":"$18.0 million","newsHeadline":"Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement for Omilancor and NX-13","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn\u2019s Disease with the Icahn School of Medicine at Mount Sinai","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Landos Phase 2 Data of Omilancor in Ulcerative Colitisr Oral Presentation","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"NIMML Institute","sponsor":"NImmune Biopharma","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"NImmune Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Josep Bassaganya-Riera Launches NImmune Biopharma with Phase 3-Ready Clinical Candidate Omilancor for the Treatment of Ulcerative Colitis and Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"NImmune Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NImmune Biopharma Provides Update on Omilancor Clinical Development Programs in Ulcerative Colitis and Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Omilancor

    Menu

    Omilancor

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              NImmune Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NImmune Biopharma Provides Update on Omilancor Clinical Development Programs in Ulcerative Colitis and Crohn’s Disease

              Details:

              BT-11 (omilancor) is a novel, oral, gut-restricted therapeutic targeting the lanthionine synthetase C-like 2 (LANCL2) pathway which decreases the production of key inflammatory mediators causing ulcerative colitis.

              Lead Product(s): Omilancor

              Therapeutic Area: Gastroenterology Product Name: BT-11

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 17, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NIMML Institute

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pip...

              Details:

              NIMML will utilize its proprietary TITAN-X drug development platform, advanced computational modeling, A.I., and bioinformatics capabilities to implement biomarker-driven approaches in NImmune’s upcoming trials involving its LANCL therapeutics, including BT-11 (omilancor).

              Lead Product(s): Omilancor

              Therapeutic Area: Gastroenterology Product Name: BT-11

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: NImmune Biopharma

              Deal Size: $15.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration May 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Landos Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Josep Bassaganya-Riera Launches NImmune Biopharma with Phase 3-Ready Clinical Candidate Omilancor for the Treatment of Ulcerative Colitis and Crohn’s Disease

              Details:

              BT-11 (omilancor) is a novel, oral, gut-restricted therapeutic targeting the lanthionine synthetase C-like 2 (LANCL2) pathway which decreases the production of key inflammatory mediators causing ulcerative colitis.

              Lead Product(s): Omilancor

              Therapeutic Area: Gastroenterology Product Name: BT-11

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: NImmune Biopharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Landos Biopharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn’s Disease with the Icahn School of Medicine at Mount Sinai

              Details:

              Landos Biopharma collaborate with Icahn School of Medicine to conduct a Phase 2 trial of omilancor, a novel, oral, gut-restricted, small-molecule investigational drug that targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway impacting the gastrointestinal tract.

              Lead Product(s): Omilancor

              Therapeutic Area: Gastroenterology Product Name: BT-11

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Icahn School of Medicine

              Deal Size: $3.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration September 20, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Landos Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Landos Phase 2 Data of Omilancor in Ulcerative Colitisr Oral Presentation

              Details:

              Discovered using Landos proprietary LANCE® Advanced A.I. platform, omilancor is a novel, oral, gut-restricted small molecule investigational drug that targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway impacting the gastrointestinal tract.

              Lead Product(s): Omilancor

              Therapeutic Area: Gastroenterology Product Name: BT-11

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Landos Biopharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement for Omilancor and NX-13

              Details:

              LianBio will receive exclusive rights to develop and commercialize BT-11 and NX-13 in Greater China, South Korea, Singapore, Thailand, Vietnam, Myanmar, Cambodia, Indonesia, and the Philippines.

              Lead Product(s): Omilancor

              Therapeutic Area: Gastroenterology Product Name: BT-11

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: LianBio

              Deal Size: $218.0 million Upfront Cash: $18.0 million

              Deal Type: Collaboration May 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY